As a group of experimental gene therapies—potentially long-lasting, if not permanent treatments—for the blood disease hemophilia continue to creep through clinical testing, a few things have become clear. They’re helping patients produce meaningful amounts of the blood-clotting proteins they lack for... Read more »
We’re only one day away from State of the Biotech Union, Xconomy’s annual Bay Area life sciences forum, which will take place tomorrow afternoon (December 6) at the Amgen Campus in South San Francisco. For you late decision-makers, you’re almost... Read more »
Are your security measures good enough?
We’re not talking about the locks on your house. We’re talking about the security of your sensitive personal data—health records, bank account passwords, and more—and the cyber defenses protecting businesses’ computer systems, data, files, intellectual... Read more »
[Updated, 12/5/16, 4 p.m. See below.] If you’re following cancer immunotherapy, you might feel a bit swamped by this week’s wave of clinical data from experimental programs that turn living T cells into revved-up cancer fighters.
We’re updating our... Read more »
The Global Innovation Exchange, a joint effort of the University of Washington and China’s Tsinghua University, is establishing some new models for intellectual property as it begins training what backers hope will be a new generation of innovation leaders.
Graduate students... Read more »
Keep up with the latest news from Wisconsin’s innovation community, starting with these recent headlines:
—Takeda, a pharmaceutical company based in Japan, is developing a vaccine for Zika virus at the laboratory it operates in Madison, the Wisconsin State Journal reported... Read more »
A diabetes drug jointly marketed by Eli Lilly (NYSE: LLY) and German pharmaceutical company Boehringer Ingelheim has won FDA approval expanding its use to include reducing the risk of cardiovascular death in diabetes patients.
The FDA initially approved empagliflozin (Jardiance)... Read more »
[Updated, 12/5/16, see below] Earlier this year, Celgene passed on an exclusive option to buy Acetylon Pharmaceuticals. But surprisingly, the two companies have come up with a new deal instead. Celgene agreed Friday to acquire just a portion... Read more »